STAMBPL1 and kidney cancer: Metastasis, the primary contributor to mortality in kidney cancer, remains obstacle for the substantial treatment, and uncovering the underlying mechanism of this process will provide novel therapeutic strategy for mRCC patients.[47] Previous studies have demonstrated that the EMT developmental program and mesenchymal phenotype could be hijacked by cancer cells to facilitate invasion and initiate metastasis.[48] Given the significant role of STAMBPL1 in mesenchymal phenotype and immune evasion of KIRC cells, we next examined the impact of STAMBPL1 on tumor metastasis.